
Sign up to save your podcasts
Or


Moderator: Francesco Di Lorenco (Rome, Italy)
Guest: Dag Aarsland (London, United Kingdom)
Francesco Di Lorenco and Prof. Dag Aarsland discuss managing behavioral symptoms in dementia, highlighting the burden on patients and families. They stress the importance of timely treatment and challenges in diagnosis. They mention brexpiprazole's FDA approval for Alzheimer's agitation and the need for careful monitoring. Early detection of psychiatric symptoms in neurological diseases is crucial, but distinguishing between disorders is challenging. Therapeutic options like clozapine and cholinesterase inhibitors are mentioned, calling for more research and collaboration.
By ean.orgModerator: Francesco Di Lorenco (Rome, Italy)
Guest: Dag Aarsland (London, United Kingdom)
Francesco Di Lorenco and Prof. Dag Aarsland discuss managing behavioral symptoms in dementia, highlighting the burden on patients and families. They stress the importance of timely treatment and challenges in diagnosis. They mention brexpiprazole's FDA approval for Alzheimer's agitation and the need for careful monitoring. Early detection of psychiatric symptoms in neurological diseases is crucial, but distinguishing between disorders is challenging. Therapeutic options like clozapine and cholinesterase inhibitors are mentioned, calling for more research and collaboration.

496 Listeners

300 Listeners

8 Listeners

48 Listeners

1,153 Listeners

22 Listeners

513 Listeners

132 Listeners

10 Listeners

252 Listeners

178 Listeners

6 Listeners

29,173 Listeners

0 Listeners

79 Listeners